Group 1: Business Strategy and Product Development - The company plans to continue expanding its OBM (Original Brand Manufacturer) business while ensuring product quality control, which is crucial for brand reputation [1] - Recent initiatives include enhancing production capacity and optimizing product categories to improve overall gross margin, laying a solid foundation for sustainable development [2] - The company has successfully passed consistency evaluations for several generic drugs and obtained registration certificates for various products, indicating a strong focus on R&D [2] Group 2: Financial Performance and Shareholder Returns - The cash dividend for the year is set at 210 million yuan, representing 43.57% of the company's net profit, with a dividend yield of 3%-4% [2] - The company achieved an investment return of over 70 million yuan through self-owned funds, ensuring capital safety [3] - Management has expressed confidence in meeting performance targets for the 2024 employee stock ownership plan, focusing on revenue and net profit [3] Group 3: Corporate Governance and Market Position - The management team has actively supported the company's long-term development by purchasing shares, demonstrating confidence in the company's future [3] - The company has maintained a high cash dividend ratio over the past two years, reinforcing its commitment to shareholder returns [3] - Concerns regarding the quality of products from a subsidiary were addressed, emphasizing compliance with national regulations and standards [3]

证券代码：000650 证券简称：仁和药业 公告编号：2025-024 仁和药业股份有限公司 第九届董事会第二十七次临时会议决议公告 本公司及其董事、监事、高级管理人员保证信息披露内容的真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 仁和药业股份有限公司第九届董事会第二十七次临时会议通知于 2025 年 5 月 10 日以直接送达、电子邮件等方式发出，会议于 2025 年 5 月 12 日以通讯方 式在南昌元创国际 18 层公司会议室召开。会议应到董事 9 人，实到董事 9 人。 董事长杨潇先生主持本次会议，会议符合《公司法》和《公司章程》的有关规定。 经与会董事认真审议，会议审议通过了如下议案： 一、审议通过了《关于撤销提名季冬凌女士为第十届董事会非独立董事候 选人的议案》 鉴于季冬凌女士因个人工作安排的原因，提出放弃第十届董事会非独立董事 候选人资格，经公司董事会审议决定，撤销对季冬凌女士第十届董事会非独立董 事候选人的提名，同时取消公司 2024 年度股东大会议案 8.00《关于董事会换届 选举非独立董事的议案》的子议案"8.04 关于选举季冬凌女士为公司第十届董 事会非独立董事"。 此议案表 ...

证券代码：000650 证券简称：仁和药业 公告编号：2025-023 仁和药业股份有限公司 届时将在线就公司2024年度业绩、公司治理、发展战略、经营状况、融资计 划、股权激励和可持续发展等投资者关心的问题，与投资者进行沟通与交流，欢 迎广大投资者踊跃参与！ 特此公告 仁和药业股份有限公司 董事会 关于参加江西辖区上市公司 2025 年投资者 网上集体接待日活动的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 为进一步加强与投资者的互动交流，仁和药业股份有限公司（以下简称"公 司"）将参加由江西省上市公司协会举办的"2025年江西辖区上市公司投资者网 上集体接待日活动"，现将相关事项公告如下： 本次活动将采用网络远程的方式举行，投资者可登录"全景路演"网站 （http://rs.p5w.net），或关注微信公众号：全景财经，或下载全景路演APP， 参与本次互动交流，活动时间为2025年5月21日（周三）15:30-17:00。 二〇二五年五月十二日 ...

证券代码：000650 证券简称：仁和药业 公告编号：2025-025 仁和药业股份有限公司 关于召开 2024 年度股东大会的补充通知 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚假记载、误导性陈 述或重大遗漏。 重要内容提示： 仁和药业股份有限公司（以下简称"公司"）于 2025 年 4 月 26 日在《证券日报》 《证券时报》《中国证券报》和巨潮资讯网（www.cninfo.com.cn）发布了《关于召 开 2024 年度股东大会的通知》。季冬凌女士因个人工作安排的原因，提出放弃第十 届董事会非独立董事候选人资格，经公司董事会审议决定，撤销对季冬凌女士第十届 董事会非独立董事候选人的提名，同时取消公司 2024 年度股东大会议案 8.00《关于 董事会换届选举非独立董事的议案》的子议案"8.04 关于选举季冬凌女士为公司第十 届董事会非独立董事"，上述事项已经公司于 2025 年 5 月 12 日召开的第九届董事会 第二十七次临时会议审议通过。 鉴于公司董事会拟撤销对季冬凌女士的非独立董事候选人提名，公司持股 5%以上 股份股东杨潇先生（持有公司 91,380,000 股,占公司总股 ...

证券代码：000650 证券简称：仁和药业 公告编号：2025-024 仁和药业股份有限公司 第九届董事会第二十七次临时会议决议公告 本公司及其董事、监事、高级管理人员保证信息披露内容的真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 仁和药业股份有限公司第九届董事会第二十七次临时会议通知于 2025 年 5 月 10 日以直接送达、电子邮件等方式发出，会议于 2025 年 5 月 12 日以通讯方 式在南昌元创国际 18 层公司会议室召开。会议应到董事 9 人，实到董事 9 人。 董事长杨潇先生主持本次会议，会议符合《公司法》和《公司章程》的有关规定。 经与会董事认真审议，会议审议通过了如下议案： 一、审议通过了《关于撤销提名季冬凌女士为第十届董事会非独立董事候 选人的议案》 1 案如下： 鉴于季冬凌女士因个人工作安排的原因，提出放弃第十届董事会非独立董事 候选人资格，经公司董事会审议决定，撤销对季冬凌女士第十届董事会非独立董 事候选人的提名，同时取消公司 2024 年度股东大会议案 8.00《关于董事会换届 选举非独立董事的议案》的子议案"8.04 关于选举季冬凌女士为公司第十届董 事会非独立董事 ...

Group 1: Financial Performance - In 2024, the company's operating revenue decreased by 19.02% year-on-year, and net profit decreased by 15.05% year-on-year due to factors such as national centralized procurement and medical insurance cost control policies [2] - The company repurchased 100 million yuan worth of shares in 2024, with no current plans for further share buybacks [2] - The gross margin improved year-on-year due to some product price increases in 2024 [5] Group 2: Research and Development - The company has significantly invested in R&D, with a 7.49% year-on-year increase in R&D expenditure in 2024 [3] - The company has successfully passed consistency evaluations for several generic drugs and obtained multiple drug registration certificates [3] Group 3: Product Categories and Market Strategy - The company's health products include functional cosmetics, skincare, maternal and infant products, health foods, medical devices, and traditional Chinese medicine [3] - In 2024, the company generated 1.132 billion yuan in sales revenue from health-related products, with plans to enhance market share through differentiated competition [6] Group 4: Future Development Focus - The company aims to achieve dual growth in operating revenue and net profit in 2025, focusing on commercial sales, innovative models, and enhancing brand strength [4] - The company plans to transition from a traditional pharmaceutical company to a leader in health lifestyle management, emphasizing sustainable value creation for shareholders [5] Group 5: Industry Outlook - The global pharmaceutical industry is expected to maintain a stable growth trajectory, driven by advancements in medical technology and increasing health awareness among consumers [6]

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：000650 证券简称：仁和药业 公告编号：2025-022 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、 误导性陈述或重大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息 的真实、准确、完整。 3.第一季度报告是否经审计 □是 R否 一、主要财务数据 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是 R否 （二） 非经常性损益项目和金额 R适用 □不适用 单位：元 其他符合非经常性损益定义的损益项目的具体情况 □适用 R不适用 将《公开发行证券的公司信息披露解释性公告第1号——非经常性损益》中列举的非经常性损益项目界 定为经常性损益项目的情况说明 □适用 R不适用 公司不存在将《公开发行证券的公司信息披露解释性公告第1号——非经常性损益》中列举的非经常性 损益项目界定为经常性损益 ...

Financial Performance - The company's revenue for Q1 2025 was ¥985,645,075.41, a decrease of 20.36% compared to ¥1,237,638,493.59 in the same period last year[5]. - Net profit attributable to shareholders was ¥164,307,562.31, down 7.33% from ¥177,296,535.93 year-on-year[5]. - The company's basic earnings per share decreased by 7.27% to ¥0.1174 from ¥0.1266 in the same period last year[5]. - Total operating revenue for the current period was ¥985,645,075.41, a decrease of 20.3% compared to ¥1,237,638,493.59 in the previous period[18]. - Net profit for the current period is CNY 196,735,645.41, a decrease of 6.4% from CNY 209,797,170.22 in the previous period[19]. - Total profit for the current period is CNY 248,377,205.20, down from CNY 264,397,235.57, reflecting a decline of 6.1%[19]. - Operating profit is CNY 248,844,587.57, compared to CNY 264,857,980.25 in the previous period, a decrease of 6.1%[19]. - The company reported a decrease in sales revenue from CNY 1,123,806,180.63 to CNY 853,461,972.41, a decline of 24.0%[20]. Cash Flow and Investments - The net cash flow from operating activities increased by 4.95% to ¥118,285,334.56 from ¥112,704,408.96 in the previous year[5]. - Cash and cash equivalents decreased to ¥522,924,601.84 from ¥2,328,656,330.79, a decline of 77.5%[15]. - Total cash inflow from investment activities is CNY 2,223,679,811.94, up from CNY 1,947,361,618.95, representing an increase of 14.1%[21]. - Cash outflow from investment activities totaled CNY 4,152,836,101.26, compared to CNY 3,545,601,855.15 in the previous period, an increase of 17.1%[21]. - Net cash flow from investment activities is CNY -1,929,156,289.32, worsening from CNY -1,598,240,236.20 in the previous period[21]. - Cash and cash equivalents at the end of the period stand at CNY 512,532,943.79, down from CNY 1,072,179,009.12, a decrease of 52.3%[21]. Assets and Liabilities - Total assets at the end of the reporting period were ¥7,651,458,277.84, reflecting a 2.26% increase from ¥7,482,460,028.05 at the end of the previous year[5]. - Total liabilities decreased to ¥644,672,981.39 from ¥676,477,512.41, a reduction of 4.7%[16]. - The company’s total equity increased to ¥7,006,785,296.45 from ¥6,805,982,515.64, an increase of 2.9%[17]. - The company reported a significant increase in accounts receivable, rising to ¥556,363,683.20 from ¥365,723,160.00, an increase of 52.1%[15]. Expenses - Research and development expenses increased by 25.67% to ¥8,129,206.47, attributed to higher costs in technical development materials and evaluations[8]. - The company experienced a 46.61% reduction in selling expenses, which amounted to ¥93,047,616.52, mainly due to decreased wages and advertising costs[8]. - The company reported a 63.05% decrease in taxes paid, totaling ¥68,244,310.79, influenced by lower income and policy impacts[8]. - Dividend distribution to minority shareholders decreased by 87.42% to ¥2,160,774.19 compared to ¥17,183,054.46 last year[9]. Shareholder Information - The total number of common shareholders at the end of the reporting period was 108,463[11]. - The largest shareholder, Renhe (Group) Development Co., Ltd., holds 23.24% of shares, totaling 325,299,386 shares[11]. - The second-largest shareholder, Yang Xiao, holds 6.53% of shares, totaling 91,380,000 shares, with 68,535,000 shares pledged[11]. - The company did not have any preferred shareholders with voting rights restored during the reporting period[11]. - There were no significant changes in the top 10 shareholders' participation in margin trading activities[12]. - The company did not engage in stock repurchase activities during the reporting period, contrasting with the previous year[9].

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：000650 证券简称：仁和药业 公告编号：2025-016 本公司及其董事、监事、高级管理人员保证信息披露内容的真实、准确、完整，没有虚假记载、误导性 陈述或重大遗漏。 提名人仁和药业股份有限公司董事会现就提名涂书田为仁和药业股份有限公司第十届董事会独立董事候 选人发表公开声明。被提名人已书面同意作为仁和药业股份有限公司第十届董事会独立董事候选人（参 见该独立董事候选人声明）。本次提名是在充分了解被提名人职业、学历、职称、详细的工作经历、全 部兼职、有无重大失信等不良记录等情况后作出的，本提名人认为被提名人符合相关法律、行政法规、 部门规章、规范性文件和深圳证券交易所业务规则对独立董事候选人任职资格及独立性的要求，具体声 明并承诺如下事项： 一、被提名人已经通过仁和药业股份有限公司第九届董事会提名委员会或者独立董事专门会议资格审 查，提名人与被提名人不存在利害关系或者其他可能影响独立履职情形的密切关系。 √ 是 □ 否 二、被提名人不存在《中华人民共和国公司法》第一百四十六条等规定不得担任公司董事的情形。 √ 是 □ 否 三、被提名人符合中国证监会 ...

证券代码：000650 证券简称：仁和药业 公告编号：2025-003 仁和药业股份有限公司 关于获得政府补助的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 仁和药业股份有限公司 三、备查文件 1、收款凭证。 特此公告 二、补助的类型及其对上市公司的影响 1.补助的类型：根据《企业会计准则第 16 号-政府补助》的规定，与资产相 关的政府补助，是指企业取得的、用于购建或以其他方式形成长期资产的政府补 助；与收益相关的政府补助，是指除与资产相关的政府补助之外的政府补助。上 述政府补助系与收益相关。 2.补助的确认和计量：根据《企业会计准则第 16 号-政府补助》的相关规定， 公司获得的上述政府补助均属于与收益相关的政府补助，且与公司日常经营活动 相关，公司将计入"其他收益"。 3.补助对上市公司的影响：上述政府补助 5,205.45 万元列入其他收益，预 计对公司 2025 年度的利润总额产生正面影响，具体的会计处理及其对公司相关 财务数据的影响将以会计师事务所年度审计确认后的结果为准，敬请广大投资者 注意投资风险。 1 一、获取补助的基本情况 近日，仁 ...